United States Patent 7,550,440: Claim Scope, Soolantra Exclusivity, and Ivermectin Rosacea Patent Landscape

United States Patent 7,550,440 covers a specific topical ivermectin emulsion and methods of using that emulsion to treat rosacea. Its four claims divide into two categories: method-of-treatment claims for 1.0% and 1.4% ivermectin emulsions, and composition claims for the same two concentrations. The claims are narrower than a general claim to topical ivermectin but can create meaningful infringement risk for products that substantially replicate the claimed excipient system.

The patent is associated with Galderma’s ivermectin 1% rosacea product, Soolantra. It is a small-molecule drug patent, so generic competition proceeds through the ANDA pathway rather than the biosimilar pathway. The commercial importance of the patent depends on its Orange Book listing, any later Galderma formulation patents, the patent term adjustment, and pending or resolved ANDA litigation.

What does United States Patent 7,550,440 cover?

Patent 7,550,440 covers an oil-in-water topical pharmaceutical emulsion containing ivermectin, glycerol, specified emulsion stabilizers, preservatives, surfactants, emollients, dimethicone, pH adjustment components, and water.

The claims cover four configurations:

Claim	Claim type	Ivermectin concentration	Core subject
1	Method of treatment	1.00 wt%	Topical application to affected skin for rosacea
2	Method of treatment	1.4 wt%	Topical application to affected skin for rosacea
3	Composition	1.00 wt%	Stable, topically applicable pharmaceutical emulsion
4	Composition	1.4 wt%	Stable, topically applicable pharmaceutical emulsion

The formulation contains 17 identified components or formulation controls, including ivermectin, glycerol, carbomer-type acrylate crosspolymer, fatty alcohols, surfactants, preservatives, dimethicone, sodium hydroxide, and water.

The key commercial formulation is the 1.0% ivermectin emulsion covered by claims 1 and 3. Claims 2 and 4 cover a 1.4% version that appears to be a separate concentration embodiment rather than the marketed 1.0% product.

How broad are the claims of Patent 7,550,440?

The claims are composition-specific, not molecule-wide.

A competitor generally would not infringe merely by selling a topical ivermectin product. Literal infringement requires the accused product or process to satisfy each material limitation of the asserted claim. For the composition claims, that means the product must contain the recited formulation components in the claimed amounts or in amounts legally construed to correspond to those limitations.

The claims are strengthened by the use of “comprising.” That term generally permits additional ingredients unless the additional ingredient changes the claimed formulation or otherwise defeats a claim limitation. A generic manufacturer cannot automatically avoid infringement by adding a minor excipient.

The claims are narrowed by the detailed formula. The listed limitations include:

Ivermectin at 1.00 wt% or 1.4 wt%;
Glycerol at 4.0 wt%;
Acrylates/C10-30 alkyl acrylate crosspolymer at 0.2 wt%;
Isopropyl palmitate at 4.0 wt%;
Cetyl alcohol at 3.5 wt%;
Oleyl alcohol at 2.0 wt%;
Ceteareth-20 at 3.0 wt%;
Sorbitan monostearate at 2.0 wt%;
Dimethicone at 0.5 wt%;
Propylene glycol at 2.0 wt%;
Phenoxyethanol at 1.0 wt%;
Methyl parahydroxybenzoate at 0.2 wt%;
Propyl parahydroxybenzoate at 0.1 wt%;
Disodium EDTA at 0.05 wt%;
Citric acid monohydrate at 0.05 wt%;
Sodium hydroxide sufficient to adjust pH; and
Water sufficient to bring the emulsion to 100 wt%.

The use of “qs pH” and “qs 100” makes sodium hydroxide and water formulation-adjustment limitations rather than fixed numerical concentrations.

What is the significance of the difference between stearyl monostearate and stearyl alcohol?

The supplied claims contain a material internal discrepancy.

Claim 1 recites “stearyl monostearate 2.5,” while claims 2, 3, and 4 recite “stearyl alcohol 2.5.” Those are different excipients:

Stearyl alcohol is a fatty alcohol used as a consistency agent and emollient.
Stearyl monostearate is a waxy ester with different chemical and functional properties.

This distinction matters for both infringement and claim construction. A product containing stearyl alcohol may satisfy claims 2 through 4 as supplied but would not literally satisfy claim 1’s stearyl monostearate limitation. Conversely, a product containing stearyl monostearate could raise a different issue under claims 1, 3, or 4 depending on the authoritative patent text.

The issued patent, certified file history, and any correction certificate control over a transcription supplied outside the official record. A formulation comparison should therefore use the exact claims in the USPTO patent record and the Orange Book-listed patent information.

Do claims 1 and 2 cover rosacea treatment or only the formulation?

Claims 1 and 2 are method-of-treatment claims. They require:

An individual in need of treatment;
Rosacea as the treatment target;
Topical application to the affected skin area; and
Use of the specified ivermectin emulsion.

A generic applicant may attempt to avoid direct method infringement by labeling its product for a different indication. That strategy does not necessarily eliminate risk. FDA labeling, promotional activity, physician instructions, product design, and induced-infringement theories can all matter.

Claims 3 and 4 are composition claims and do not require a rosacea-treatment step in the claim language supplied. They therefore present a broader enforcement vehicle against the manufacture, sale, offer for sale, or importation of a matching formulation.

What formulations are protected by Patent 7,550,440?

The patent protects formulations that materially replicate the claimed excipient architecture.

1.0% ivermectin formulation

The 1.0% claims are the most directly relevant to Soolantra. They require a formulation containing ivermectin at 1.00 wt% with the specified base, emulsifiers, preservatives, fatty components, and water system.

A generic product using 1.0% ivermectin but replacing several excipients may have a stronger noninfringement position. A product using the same qualitative formulation and nearly identical quantitative amounts would face greater risk.

1.4% ivermectin formulation

Claims 2 and 4 cover a 1.4% ivermectin formulation. A product containing 1.4% ivermectin does not necessarily infringe the 1.0% claims, because concentration is an express limitation. It may, however, fall within claims 2 and 4 if the remaining formulation limitations are met.

Stable-emulsion limitation

Claims 3 and 4 describe a “stable pharmaceutical emulsion.” Stability may require evidence involving physical separation, viscosity, particle distribution, chemical degradation, freeze-thaw performance, accelerated aging, or shelf-life testing. A product that contains the listed ingredients but does not satisfy the applicable stability construction may contest that limitation.

Stability is also a potential litigation issue because the patent claim does not necessarily specify one universal test or numerical threshold. The specification and prosecution history would be important in determining the scope of the term.

When does Patent 7,550,440 lose exclusivity?

The patent issued on June 23, 2009. Its enforceable expiration date cannot be determined from the issue date alone. The controlling date depends on the patent’s earliest effective nonprovisional filing date, any patent term adjustment, any terminal disclaimer, and the official USPTO term calculation.[1]

For Soolantra, the practical exclusivity analysis must distinguish:

Exclusivity component	Relevant issue
Patent 7,550,440	Formula and method claims for ivermectin emulsion
FDA new-drug exclusivity	Regulatory exclusivity attached to the NDA
Orange Book listing	Determines notice and litigation consequences for ANDA applicants
Later Galderma patents	May extend protection beyond the expiration of the ’440 patent
Pediatric exclusivity	May add six months if granted and applicable
Patent term adjustment	May move the expiration date beyond the base term

The FDA-approved product labeling and Orange Book patent table should be used for the operative expiration date and listing status.[2,3] Patent expiration does not automatically mean immediate generic availability if later unexpired patents remain listed or enforceable.

What is the Orange Book status of Patent 7,550,440?

Patent 7,550,440 has been associated with the Soolantra ivermectin 1% cream product and should be evaluated as an Orange Book-listed drug patent rather than as an isolated formulation patent.[2]

An Orange Book listing has several consequences:

An ANDA applicant must address the listed patent through a Paragraph I, II, III, or IV certification.
A Paragraph IV certification alleges that the patent is invalid, unenforceable, or will not be infringed.
The NDA holder may bring suit within 45 days of receiving Paragraph IV notice.
Timely patent litigation can trigger a statutory 30-month stay of final ANDA approval, subject to court and FDA rules.
The first substantially complete ANDA with a qualifying Paragraph IV certification may receive 180-day exclusivity, depending on the statutory circumstances.

The listing must be checked against the current Orange Book because patent listings can be changed, delisted, corrected, or supplemented by later patents.

Which companies are likely to challenge Soolantra exclusivity?

The relevant challengers are generic dermatology and specialty-pharmaceutical companies capable of filing an ANDA for ivermectin cream. Potential challengers may include companies that develop topical dermatology products, contract manufacturers with ANDA infrastructure, and large generic manufacturers.

The commercial challenge is technically more difficult than a simple active-ingredient substitution because the claimed product is a multi-excipient emulsion. A challenger can pursue one of three broad approaches:

Replicate the formulation and challenge validity or enforceability;
Design around one or more quantitative or qualitative limitations; or
Develop a different topical ivermectin formulation and rely on a noninfringement position.

Public litigation conclusions should be based on the specific defendant, ANDA number, asserted patent set, court docket, and settlement terms. The existence of an ANDA filing alone does not establish market entry.

What Paragraph IV risks exist for a generic ivermectin cream?

A Paragraph IV challenge to Patent 7,550,440 would likely focus on four areas.

Anticipation and obviousness

A challenger could argue that prior art disclosed ivermectin topical treatment, conventional oil-in-water emulsions, or the claimed excipient combination. The patent’s defense would depend on whether the prior art disclosed the precise formulation and whether the claimed combination produced unexpected stability, tolerability, penetration, or efficacy results.

Written description and enablement

The claims recite a detailed formulation, so written-description risk may be lower than for a broad genus claim. Enablement issues could still arise if the claim covers a range of formulations or manufacturing conditions not adequately supported by the specification.

Claim construction

Disputes may concern:

The meaning of “stable”;
The significance of fixed numerical concentrations;
Whether “comprising” permits material excipient substitutions;
Whether “topically applicable” imposes a functional requirement;
The identity of the stearyl component; and
Whether the method claims require a particular dosing frequency or duration.

Infringement by equivalent formulation

A generic may replace an excipient or vary a concentration while preserving the same function and result. Galderma could pursue a doctrine-of-equivalents theory, subject to prosecution-history estoppel and the all-elements rule. A deliberate design-around should avoid changes that are merely insubstantial.

How does this patent compare with a typical active-ingredient patent?

Patent 7,550,440 is narrower than a patent claiming ivermectin for all dermatological uses, but it may be more commercially relevant to a branded cream because it maps to the finished dosage form.

Patent type	Typical scope	Relevance to generic cream
Ivermectin compound patent	Active molecule	Usually expired or irrelevant to modern ivermectin products
Rosacea method patent	Use of ivermectin for rosacea	Depends on label and prescribing conduct
Formulation patent	Specific emulsion and excipient system	Directly relevant to product composition
Manufacturing patent	Process parameters or equipment	Relevant only if the generic uses the protected process
Device or packaging patent	Container, pump, or delivery system	May affect commercial packaging rather than core formulation

The ’440 patent’s primary value is its product-formulation coverage combined with rosacea method claims.

Are biosimilars a risk for Soolantra?

No. Ivermectin is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application under section 351(k) of the Public Health Service Act.

A generic applicant must address pharmaceutical equivalence, bioequivalence, quality, manufacturing, labeling, and listed patents. FDA may require product-specific bioequivalence evidence appropriate to the topical dosage form.

What manufacturing and intellectual-property barriers remain?

The formulation includes several interacting components that can create development and scale-up barriers:

Carbomer-type polymer hydration and neutralization;
Control of emulsion droplet size;
Uniform ivermectin distribution;
Compatibility between preservatives and surfactants;
Viscosity control from fatty alcohols and polymer;
pH control using sodium hydroxide and citric acid;
Long-term physical and chemical stability; and
Reproducible filling into the commercial container.

These technical issues do not independently prove patent infringement. They can, however, raise development costs and make a close formulation design-around harder to commercialize.

Manufacturing-process patents, know-how, analytical methods, and supplier specifications may create additional barriers even after the ’440 patent expires. Those rights must be evaluated separately from the composition claims.

What is the likely generic launch risk?

Generic launch risk depends on the interaction of patent term, Orange Book listings, Paragraph IV litigation, FDA approval timing, and settlement restrictions.

Launch scenario	Commercial implication
No Paragraph IV challenge	Entry generally waits for patent and regulatory barriers to clear
Paragraph IV with no timely suit	FDA approval may proceed subject to applicable exclusivity
Paragraph IV followed by litigation	Approval may be stayed for up to 30 months under the statutory framework
Settlement with licensed entry date	Entry occurs according to the negotiated date and conditions
Formulation design-around	Earlier entry may be possible if FDA approves a noninfringing product
Patent expiry with no later blocking patent	Broadest opportunity for generic launch

A precise market-entry forecast cannot rely on Patent 7,550,440 alone. Later patents listed for Soolantra and any litigation settlements may control actual entry.

How strong is the patent estate for ivermectin rosacea products?

The ’440 patent has moderate formulation strength and narrower molecule-level breadth.

Its strengths are:

Direct coverage of the 1.0% formulation associated with Soolantra;
Separate coverage of a 1.4% concentration;
Both composition and method claims;
Detailed excipient architecture that may be difficult to copy exactly; and
Potential Orange Book leverage against ANDA applicants.

Its limitations are:

No broad claim to all topical ivermectin products;
Dependence on exact formulation limitations;
Potential design-around opportunities;
Possible ambiguity concerning stearyl monostearate versus stearyl alcohol;
Potential validity challenges based on prior topical ivermectin and emulsion art; and
Expiration governed by the official patent-term calculation.

Key Takeaways

Patent 7,550,440 contains four supplied claims: two rosacea-treatment claims and two stable-emulsion composition claims.
Claims 1 and 3 cover 1.00% ivermectin; claims 2 and 4 cover 1.4% ivermectin.
The patent does not broadly cover every topical ivermectin product.
The principal infringement risk arises from copying the full excipient system and quantitative formulation.
The discrepancy between “stearyl monostearate” in claim 1 and “stearyl alcohol” in claims 2 through 4 is material.
Soolantra faces generic, not biosimilar, competition.
Paragraph IV litigation, later Orange Book patents, patent term adjustment, and settlement agreements may determine actual generic entry.
The exact expiration date must be taken from the official USPTO term record and current FDA Orange Book listing, not inferred from the issue date.
Formulation design-around strategies can focus on the stearyl component, surfactant system, polymer, preservative system, concentration, or quantitative amounts.
The ’440 patent is commercially important because it targets the finished topical formulation rather than only the ivermectin active ingredient.

FAQs

Does a generic cream with 1% ivermectin automatically infringe Patent 7,550,440?

No. It must also satisfy the other composition limitations, including the specified excipients and amounts, or create a legally actionable equivalent.

Can a manufacturer avoid the patent by changing only the preservative?

Possibly, but the result depends on whether the preservative is a required claim limitation, whether the modified product still contains an equivalent component, and whether other claims or later patents cover the revised formulation.

Does a rosacea indication create greater risk than an off-label ivermectin product?

Yes. Claims 1 and 2 expressly require treatment of rosacea. Labeling, promotional conduct, and intended use can affect method-of-treatment infringement analysis.

Can a 1.4% ivermectin product infringe the 1.0% claims?

A literal infringement case would face the express concentration limitation. The 1.4% product should instead be analyzed against claims 2 and 4 and any later patents.

Is FDA approval possible before all Soolantra patents expire?

Yes, depending on the certification, litigation status, statutory stay, regulatory exclusivity, and any settlement or license governing launch.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information. https://www.uspto.gov/patents/laws/patent-term-adjustment
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. Food and Drug Administration. (2014). Soolantra (ivermectin) cream, 1%: Prescribing information. https://www.accessdata.fda.gov/drugsatfda/
United States Patent and Trademark Office. (2009). U.S. Patent No. 7,550,440, Ivermectin-containing pharmaceutical composition for topical application. https://patents.google.com/patent/US7550440
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	03 05048	Apr 24, 2003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1620113	⤷ Start Trial	C300756	Netherlands	⤷ Start Trial
European Patent Office	1620113	⤷ Start Trial	CA 2015 00045	Denmark	⤷ Start Trial
European Patent Office	1620113	⤷ Start Trial	PA2015033	Lithuania	⤷ Start Trial
European Patent Office	1620113	⤷ Start Trial	122015000079	Germany	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,550,440

Summary for Patent: 7,550,440